Fulcrum Therapeutics Inc. (FULC)
3.21
-0.03 (-0.93%)
At close: Mar 04, 2025, 12:09 PM
Fulcrum Therapeutics Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -97.33M | -109.87M | -80.85M | -70.82M | -82.68M | -32.59M | -22.96M |
| Depreciation & Amortization | 2.17M | 2.41M | 2.52M | 2.38M | 2.05M | 1.34M | 715K |
| Stock-Based Compensation | 14.8M | 13.35M | 11.07M | 7.35M | 4.22M | 2.16M | 1.37M |
| Other Working Capital | -3.45M | -4.42M | -13.61M | 7.5M | 10.52M | 6.54M | 596K |
| Other Non-Cash Items | -5.99M | 152K | 673K | -2M | 25.59M | 4.87M | 2.59M |
| Deferred Income Tax | n/a | n/a | n/a | 1.93M | n/a | n/a | n/a |
| Change in Working Capital | -4.61M | -3.09M | -11.89M | 7.5M | 11.33M | 6.52M | 804K |
| Operating Cash Flow | -90.97M | -97.05M | -78.48M | -53.66M | -39.48M | -22.56M | -20.07M |
| Capital Expenditures | -508K | -1.96M | -1.71M | -1.34M | -853K | -8.98M | -1.91M |
| Acquisitions | n/a | -14.38M | 127.96M | 55.8M | n/a | n/a | n/a |
| Purchase of Investments | -194.89M | -151.15M | -216.23M | -124.27M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 158.71M | 165.53M | 88.28M | 68.47M | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | 14.38M | -127.96M | -55.8M | -91K | n/a | n/a |
| Investing Cash Flow | -36.69M | 12.41M | -129.67M | -57.14M | -944K | -8.98M | -1.91M |
| Debt Repayment | n/a | n/a | -18K | -50K | -45K | -70K | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 1.55M | 3.52M | 3.67M | 1.24M | 215K | 105.09M | 35.28M |
| Financial Cash Flow | 118.12M | 84.32M | 186.51M | 71.13M | 64.34M | 105.03M | 17.66M |
| Net Cash Flow | -9.54M | -314K | -21.64M | -39.66M | 23.92M | 73.48M | -4.32M |
| Free Cash Flow | -91.47M | -99.01M | -80.19M | -55M | -40.34M | -31.54M | -21.98M |